Cargando…

From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities

PURPOSE OF REVIEW: In this review, we highlight the most important cellular and molecular mechanisms that contribute to cardiac inflammation and fibrosis. We also discuss the interplay between inflammation and fibrosis in various precursors of heart failure (HF) and how such mechanisms can contribut...

Descripción completa

Detalles Bibliográficos
Autores principales: Suthahar, Navin, Meijers, Wouter C., Silljé, Herman H.W., de Boer, Rudolf A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527069/
https://www.ncbi.nlm.nih.gov/pubmed/28707261
http://dx.doi.org/10.1007/s11897-017-0343-y
_version_ 1783252910931443712
author Suthahar, Navin
Meijers, Wouter C.
Silljé, Herman H.W.
de Boer, Rudolf A.
author_facet Suthahar, Navin
Meijers, Wouter C.
Silljé, Herman H.W.
de Boer, Rudolf A.
author_sort Suthahar, Navin
collection PubMed
description PURPOSE OF REVIEW: In this review, we highlight the most important cellular and molecular mechanisms that contribute to cardiac inflammation and fibrosis. We also discuss the interplay between inflammation and fibrosis in various precursors of heart failure (HF) and how such mechanisms can contribute to myocardial tissue remodelling and development of HF. RECENT FINDINGS: Recently, many research articles attempt to elucidate different aspects of the interplay between inflammation and fibrosis. Cardiac inflammation and fibrosis are major pathophysiological mechanisms operating in the failing heart, regardless of HF aetiology. Currently, novel therapeutic options are available or are being developed to treat HF and these are discussed in this review. SUMMARY: A progressive disease needs an aggressive management; however, existing therapies against HF are insufficient. There is a dynamic interplay between inflammation and fibrosis in various precursors of HF such as myocardial infarction (MI), myocarditis and hypertension, and also in HF itself. There is an urgent need to identify novel therapeutic targets and develop advanced therapeutic strategies to combat the syndrome of HF. Understanding and describing the elements of the inflammatory and fibrotic pathways are essential, and specific drugs that target these pathways need to be evaluated.
format Online
Article
Text
id pubmed-5527069
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-55270692017-08-08 From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities Suthahar, Navin Meijers, Wouter C. Silljé, Herman H.W. de Boer, Rudolf A. Curr Heart Fail Rep Comorbidities of Heart Failure (C Angermann & F Edelmann, Section Editors) PURPOSE OF REVIEW: In this review, we highlight the most important cellular and molecular mechanisms that contribute to cardiac inflammation and fibrosis. We also discuss the interplay between inflammation and fibrosis in various precursors of heart failure (HF) and how such mechanisms can contribute to myocardial tissue remodelling and development of HF. RECENT FINDINGS: Recently, many research articles attempt to elucidate different aspects of the interplay between inflammation and fibrosis. Cardiac inflammation and fibrosis are major pathophysiological mechanisms operating in the failing heart, regardless of HF aetiology. Currently, novel therapeutic options are available or are being developed to treat HF and these are discussed in this review. SUMMARY: A progressive disease needs an aggressive management; however, existing therapies against HF are insufficient. There is a dynamic interplay between inflammation and fibrosis in various precursors of HF such as myocardial infarction (MI), myocarditis and hypertension, and also in HF itself. There is an urgent need to identify novel therapeutic targets and develop advanced therapeutic strategies to combat the syndrome of HF. Understanding and describing the elements of the inflammatory and fibrotic pathways are essential, and specific drugs that target these pathways need to be evaluated. Springer US 2017-07-13 2017 /pmc/articles/PMC5527069/ /pubmed/28707261 http://dx.doi.org/10.1007/s11897-017-0343-y Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Comorbidities of Heart Failure (C Angermann & F Edelmann, Section Editors)
Suthahar, Navin
Meijers, Wouter C.
Silljé, Herman H.W.
de Boer, Rudolf A.
From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities
title From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities
title_full From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities
title_fullStr From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities
title_full_unstemmed From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities
title_short From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities
title_sort from inflammation to fibrosis—molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities
topic Comorbidities of Heart Failure (C Angermann & F Edelmann, Section Editors)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527069/
https://www.ncbi.nlm.nih.gov/pubmed/28707261
http://dx.doi.org/10.1007/s11897-017-0343-y
work_keys_str_mv AT suthaharnavin frominflammationtofibrosismolecularandcellularmechanismsofmyocardialtissueremodellingandperspectivesondifferentialtreatmentopportunities
AT meijerswouterc frominflammationtofibrosismolecularandcellularmechanismsofmyocardialtissueremodellingandperspectivesondifferentialtreatmentopportunities
AT silljehermanhw frominflammationtofibrosismolecularandcellularmechanismsofmyocardialtissueremodellingandperspectivesondifferentialtreatmentopportunities
AT deboerrudolfa frominflammationtofibrosismolecularandcellularmechanismsofmyocardialtissueremodellingandperspectivesondifferentialtreatmentopportunities